01 Apr Broken String Biosciences
Felix Dobbs, Ph.D., CEO and Co-founder
April 15 | 4:15pm | Salone dei Cavalieri, Section 2
Cambridge, United Kingdom
(Private)
Broken String Biosciences is a genomics company with a mission to advance the next generation of more precise, safe, and effective cell and gene therapies through its cutting-edge technology platforms. The Company’s core technology, INDUCE-seq, is a Next Generation Sequencing (NGS)-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify off-target genetic edits, and evaluate the associated genetic outcomes. The platform technology provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs. Broken String Biosciences was spun out of Cardiff University in 2020 and completed a six-month residency at the Illumina Accelerator in Cambridge, UK. The Company has raised financing of $20m USD to date from venture capital investors.
